Physician profile
Eduardo Robles
NPI 1649202565
$701.89
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $53.55 · 2021: $30.39 · 2022: $40.55 · 2023: $37.89 · 2024: $13.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $188.83 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $130.19 | 2019 | |
| Gilead Sciences, INC. | $58.91 | 2019 | |
| Abbott Laboratories | $55.26 | 2021-2023 | Freestyle Libre 2 |
| Amgen INC. | $55.12 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $43.14 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.27 | 2019 | |
| Novo Nordisk INC | $29.08 | 2022-2023 | |
| Amarin Pharma, INC. | $27.82 | 2019-2020 | |
| Pfizer INC. | $24.59 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $15.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.82 | 2019 | |
| Medtronic Vascular, INC. | $11.40 | 2019 | |
| Lilly USA, LLC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.